Analyst Susan Anderson of Canaccord Genuity maintained a Buy rating on Perrigo Company, retaining the price target of $42.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Susan Anderson’s rating is based on Perrigo Company’s strategic decision to sell its dermacosmetics business, which aligns with its focus on strengthening core operations. The sale is expected to bring in significant cash, which management plans to use in accordance with their capital allocation priorities, including maintaining a healthy dividend, reinvesting in the business, reducing leverage, and potentially engaging in share buybacks or strategic acquisitions.
Furthermore, the divestiture supports Perrigo’s “Three S” Plan, which aims to stabilize its US business, streamline its portfolio, and strengthen high-growth brands. By divesting non-core assets, Perrigo is positioning itself to focus on more scalable and profitable segments, such as its oral care business. This strategic move is anticipated to aid in reducing the company’s leverage, thereby improving its financial health and enhancing shareholder value.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRGO in relation to earlier this year.

